Angiopoietin 2 (Ang-2) Inhibitor Pipeline Summary

DelveInsight’s, “Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Angiopoietin 2 (Ang-2) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Angiopoietin 2 (Ang-2) Inhibitor: Understanding

Angiopoietin 2 (Ang-2) Inhibitor: Overview

Angiopoietin-2 (Ang2) is a member of the Ang family, which plays an important role in angiogenesis during the development and growth of human cancers. Ang2’s role in angiogenesis generally is considered as an antagonist for Ang1, inhibiting Ang1-promoted Tie2 signaling, which is critical for blood vessel maturation and stabilization. Ang2 modulates angiogenesis in a cooperative manner with another important angiogenic factor, vascular endothelial growth factor A. Genetic studies have revealed that Ang2 also is critical in lymphangiogenesis during development.

Ang1 and Ang2 interact with their cognate receptor, Tie2, which is most frequently expressed in ECs. Upon binding Angs, the Tie2 receptor dimerizes and becomes phosphorylated in tyrosine residues at its C-terminal . Activated Tie2 stimulates phosphatidylinositol 3-kinase (PI3K)-dependent activation of Akt, leading to increases in cell survival, suppression of caspase 3, 7, and 9 activity, and attenuation of mitochondrial-derived activator of caspase (Smac) release. Ang1 stimulates Tie2, activating the DokR-Pak, Nck, and Grb14 pathways; inhibiting EC proliferation; and displaying an antiangiogenic property.

Ang1 also upregulates cyclin D1 expression and activates mitogen-activated protein kinase (MAPK) and PI3K in murine IBE and human umbilical vein endothelial cells. In addition, COMP-Ang1–induced vascular enlargement and blood flow are mediated mainly through Tie2 activation, and sustained Tie2 overexpression may participate in the maintenance of vascular changes. The protective role of ECs from apoptosis by Ang1 or in synergy with VEGF-A has been widely observed in vitro, in vivo, and under various stress conditions. Ang2 has been found to be an antagonist as well as an agonist for Tie2 receptor signaling in modulating EC migration and survival.

Although Ang2 modulates angiogenesis through interaction with the Tie2 receptor [29], it contains a highly conserved N-terminal fibrinogen-like receptor–binding domain that may form a functional association with certain integrin receptors. Ang1 and Ang2 were shown to stimulate Tie2-independent cell adhesion of ECs and fibroblasts to Ang1- or Ang2-coated surfaces through ?5?1 and ?v?5 integrin–mediated activation of ERK and focal adhesion kinase (FAK) signaling. Skeletal myocytes lacking Tie2 adhere to Ang1- and Ang2-coated surfaces in a similar manner as to laminin, fibronectin, and vitronectin. The Ang-stimulated skeletal myocyte adhesion is mediated by integrin receptors such as ?5?1, activating ERK and FAK signaling and promoting cell survival.

A close link between increased Ang2 expression and tumor progression, invasion, and metastasis in various types of human cancers has established Ang2’s prognostic value in predicting cancer progression and clinical outcome. Ang2’s unique roles in angiogenesis in development and progression of various types of human cancers also make Ang2 an attractive therapeutic target. In addition, Ang2 stimulates tumor angiogenesis, invasion, and metastasis through Tie2-independent pathways involving integrin-mediated signaling. Prognostic values of Ang2 expression in various types of human cancers and elevated Ang2 levels in the blood of cancer patients have established Ang2 as an attractive therapeutic target, and this was corroborated by recent studies using a neutralizing anti-Ang2 antibody.

“Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Angiopoietin 2 (Ang-2) Inhibitor pipeline landscape is provided which includes the disease overview and Angiopoietin 2 (Ang-2) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Angiopoietin 2 (Ang-2) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Angiopoietin 2 (Ang-2) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Angiopoietin 2 (Ang-2) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Angiopoietin 2 (Ang-2) Inhibitor.

Angiopoietin 2 (Ang-2) Inhibitor Emerging Drugs Chapters

This segment of the Angiopoietin 2 (Ang-2) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Angiopoietin 2 (Ang-2) Inhibitor Emerging Drugs

• IBI 324: Innovent Biologics/ Ollin Biosciences

IBI324 (OLN324) was discovered by Innovent Biologics in collaboration with Ollin Biosciences as a next-generation VEGF/Ang2 bispecific antibody engineered with substantially higher Ang2 potency than faricimab, increased molar dosing relative to both faricimab and aflibercept (including Eylea HD®), and a smaller protein format. VEGF and Ang2 are key drivers of retinal vascular diseases such as diabetic macular edema (DME) and wet (neovascular) age-related macular degeneration (wAMD), with Ang2 playing a critical role in vascular instability, leakage, inflammation, and fibrosis. In the recently completed head-to-head Phase 1b JADE clinical study comparing OLN324 with faricimab (Vabysmo), OLN324 demonstrated meaningfully faster and greater anatomical improvements in both DME and wAMD, along with numerically greater vision gains. Ollin plans to initiate global Phase III trials of OLN324 in DME and wAMD in the second half of 2026. Through its partnership with Innovent, these global Phase III trials are planned to include sites in China and South Korea.

Further product details are provided in the report……..

Angiopoietin 2 (Ang-2) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Angiopoietin 2 (Ang-2) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Angiopoietin 2 (Ang-2) Inhibitor

There are approx. 5+ key companies which are developing the therapies for Angiopoietin 2 (Ang-2) Inhibitor. The companies which have their Angiopoietin 2 (Ang-2) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Innovent Biologics, Ollin Biosciences, and others.

Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Angiopoietin 2 (Ang-2) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Angiopoietin 2 (Ang-2) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angiopoietin 2 (Ang-2) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angiopoietin 2 (Ang-2) Inhibitor drugs.

Angiopoietin 2 (Ang-2) Inhibitor Report Insights

• Angiopoietin 2 (Ang-2) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Angiopoietin 2 (Ang-2) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Angiopoietin 2 (Ang-2) Inhibitor drugs?
• How many Angiopoietin 2 (Ang-2) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angiopoietin 2 (Ang-2) Inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angiopoietin 2 (Ang-2) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Angiopoietin 2 (Ang-2) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Innovent Biologics
• Ollin Biosciences
• AskGene Pharma, Inc.
• PharmAbcine

Key Products

• IBI 324
• ASKG712
• PMC 401